Comparative Pharmacology
Head-to-head clinical analysis: BARICITINIB versus XELJANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARICITINIB versus XELJANZ.
BARICITINIB vs XELJANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Baricitinib is a Janus kinase (JAK) inhibitor, selectively inhibiting JAK1 and JAK2, thereby modulating the signaling pathway involved in inflammatory responses.
Janus kinase (JAK) inhibitor. Selectively inhibits JAK1 and JAK3, mediating signaling of cytokines/growth factors involved in immune response and hematopoiesis.
2 mg orally once daily; may increase to 4 mg once daily if inadequate response.
5 mg orally twice daily; for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. For ulcerative colitis induction, 10 mg orally twice daily for 8 weeks; maintenance at 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12.5 hours in healthy subjects; allowing once-daily dosing with steady-state reached in 2-3 days.
Clinical Note
moderateBaricitinib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Baricitinib."
Clinical Note
moderateBaricitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Cyclosporine
Terminal half-life is approximately 3.3 hours. Twice-daily dosing maintains therapeutic concentrations.
Approximately 75% of the dose is excreted in urine (69% as unchanged drug, 6% as metabolites), and 20% in feces (15% unchanged, 5% metabolites).
Approximately 70% of the dose is excreted in urine (30% as unchanged drug, 40% as metabolites) and 20% in feces (10% as unchanged drug).
Category C
Category C
JAK Inhibitor
JAK Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Baricitinib."